Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Riviciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 15/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 14/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 12/20 | 1.00 |
| ▸ | CCND1 | P24385 | 13/20 | 1.00 |
| ▸ | CDK2 | P24941 | 12/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 11/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 10/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 7/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 7/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 7/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 5/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 5/20 | 1.00 |
| ▸ | CCND3 | P30281 | 4/20 | 1.00 |
| ▸ | GSK3A | P49840 | 4/20 | 1.00 |
| ▸ | CDK7 | P50613 | 3/20 | 1.00 |
| ▸ | CCNH | P51946 | 2/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 2/20 | 1.00 |
| ▸ | MAPK15 | Q8TD08 | 2/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riviciclib SCHEMBL665749 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL665748 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL17348307 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL31702788 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL290572 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL291157 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL23683025 | 1.00 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL6119675 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL29387962 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 | |
| Riviciclib SCHEMBL290347 | 0.99 | CDK4 (1.00) | CDK4CDK1CCND1CDK9CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118021943-A | Combination therapy of chimeric antigen receptor and PD-1 inhibitor | 诺华股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117959417-A | Combination therapy of chimeric antigen receptor and PD-1 inhibitor | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117731786-A | Pharmaceutical combination for the treatment of melanoma | 皮拉马尔企业有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-111053768-B | Pharmaceutical combination for the treatment of melanoma | 皮拉马尔企业有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-116615258-A | Compositions and methods for in vivo production of CAR-expressing cells | 诺华股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116334143-A | Optimized lentiviral transfer vectors and uses thereof | 诺华股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-108603200-B | Optimized lentiviral transfer vectors and uses thereof | 诺华股份有限公司 | 2022-08-19 | — | — | CN | disclosed |